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Sleep disturbances in depression are up to 70%. Patients frequently have difﬁculty in falling
asleep, frequent awakenings during the night and non-restorative sleep. Sleep abnormalities in
depression are mainly characterized by increased rapid eye movement (REM) sleep and reduced
slow wave sleep. Among the mechanisms of sleep disturbances in depression are hyperactiva-
tion of the hypothalamic-pituitary-adrenal axis, CLOCK gene polymorphism and primary sleep
disorders. The habenula is a structure regulating the activities of monoaminergic neurons in the
brain. The hyperactivation of the habenula has also been implicated, together with sleep
disturbances, in depression. The presence of depression in primary sleep disorders is common.
Sleep disturbances treatment include pharmacotherapy or Cognitive Behavioral Therapy.
& 2014 Brazilian Association of Sleep. Production and Hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. History
Sleep is classiﬁed into 2 phases: sleep without rapid eye
movement (NREM) and sleep with REM [1,2]. REM sleep is
initiated when noradrenergic and serotonergic activities are
decreased while cholinergic activity increases [3].
Sleep alterations are common among patients with major
depression (MD) and form part of the diagnostic criteria for
this disease. Patients with MD frequently demonstrate difﬁ-
culty in initiating sleep, frequent awakenings during the
night, earlier than desired awakenings and nonrestorative
sleep [4–6]. Other main symptoms are decreased total sleep
and disturbing nightmares [7].
Several epidemiological studies demonstrated that
patients with MD have increased frequency of sleepep. Production and Hosti
licenses/by-nc-nd/3.0/).
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m, drbarrepsiq@yahoo.coabnormalities and these continue even during periods of
remission, being more common in divorced patients and
with higher scores for the anxiety subscale of the hospital
anxiety and depression scale [8]. On the other hand, patients
with persistent insomnia but without depression show a
higher risk of developing MD than in normal sleepers [9].2. Biological mechanisms for the sleep
alterations in MD
To explain the sleep abnormalities in MD, there are several
biological models, among them some for the study of neu-
roendocrinal factors, irregularities in the circadian genes and
functional, neuroanatomical neuroimaging studies. Theng by Elsevier B.V. This is an open access article under the CC BY-
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S l e e p S c i e n c e 7 ( 2 0 1 4 ) 1 6 5 – 1 6 9166neuroendocrinal factors may have an important role on sleep
abnormalities of MD, such as the corticotropin-releasing
hormone (CRH), adrenocorticotropin and cortisol [10,11].
In relation to cortisol and adrenocorticotropin hormones
are concerned, the elevated levels are observed mainly during
the night; they are markers of acute episodes of MD [12]. Some
have observed endocrinal alterations that are characteristic of
MD (decrease of slow wave sleep and increase of cortisol) in
young individuals after the administration of CRH [13]. There-
fore, an analysis has revealed that children classiﬁed as “poor”
sleepers did show an increase in cortisol during the morning,
compared with children that were normal sleepers [14].
Elevated cortisol levels, under conditions of stress, have
been associated with an increased number of intermittent
awakenings and increases time in phases N1 and N2 [14].
Furthermore, some psychological difﬁculties such as anxiety,
impulsiveness and social inhibition, which are common
ﬁndings in MD, are usually related with a decrease in sleep
efﬁciency [14].These data strengthen themselves since with
the use of CRH antagonist, R121919, in depressed patients,
there is an increase in the slow wave sleep. This suggests that
the antagonism of the corticotrophin-releasing hormone
normalizes sleep in patients with depression [15].
The intimate relationship between insomnia and depres-
sion could also be determined at a genetic level in the control
of biological rhythms. Circadian rhythms are controlled by a
synchronizer localized at the suprachiasmatic nucleus (SQN)
in the anterior hypothalamus. Among the genes that interact
with the SQN are the CLOCK genes which have an important
inﬂuence upon the sleep pattern. Some studies have indi-
cated that patients with MD have a variant in the polymorph-
ism of the CLOCK genes (they have the C alleles) [16], and
therefore suffer from initial insomnia, which becomes acute
during the antidepressant treatment, as compared with
patients who do not possess this speciﬁc variant [17,18].
Other genes implicated with MD as well as insomnia are
the polymorphisms of the monoamino-oxidase A gen and the
promoter of the serotonin transporter gene, the latter being
correlated with an insomnia of higher severity [19], as well as
citalopram side effects, an antidepressant [20].
Studies in rats have described other time marker genes,
being highlighted as the gen miRNAs-182, which codes the
endogenous modulation of the circadian cycle. An associa-
tion has been found between the delayed insomnia in
patients with MD and the presence of an upper expression
of the miRNAs-182 gene, due to the increase of its mutated
form, expressed by the T allele of the polymorphism
rs76481776, the gene pre-miR-182. This mutated form is
immature and generates deregulation of the sleep–wake cycle
due to the decrease of the blank sites of the mi RNAs-182
mature gene. This mechanism has been proposed as part of
the causing effects of the sleep disorders in patients with MD,
especially in the presence of late insomnia [21].
In healthy individuals, during No REM sleep, the metabolic
activity decreases on the frontal, temporal and parietal cor-
tices, in contrast with waking levels; individuals with MD do
show a non-signiﬁcant decrease in activity in the same areas
of waking during the beginning of sleep. It is possible that this
reduction may reﬂect a deﬁcit in the processes related to
sleep–wake cycle, present in MD as a decreased synapticpotentiation. Other brain areas involved in emotional reg-
ulation (anterior cingulate cortex, amygdala, thalamus) also
had a smaller decline in metabolic level from waking to No
REM sleep. Compared with normal individuals, these struc-
tures have an increase in metabolism during sleep.
Depressed subjects can also present an increase in meta-
bolic activity within these cortical and subcortical structures
during REM sleep, due to the fact that these alterations
reﬂect imbalance of the monoaminergic-cholinergic systems
in MD [10,22].
The habenula consists of a pair of small adjacent nuclei to
the medium dorsal thalamus. It is divided between medial
and lateral portions [23].The lateral habenula (LHb) receives
stimuli from several structures such as the internal segment
of the globus pallidus. On the other hand, LHb stimulation
inhibits the activity of serotonergic and dopaminergic neu-
rons of the brain stem and this, in turn, stimulates the
selective inhibitors of serotonin reuptake, which act upon
the axon pre-synaptic terminals to suppress LHb hyperacti-
vation. Dopamine has also an excitatory effect on the activity
of LHb, upon which the chronic activation of the dopaminer-
gic inputs of LHb contributes to the hyperactivation of the
LHb in MD. Although during sleep, some studies demon-
strated that the lesion in LHb reduces the REM sleep, due to
the fact that the activity of the LHb neurons is indispensible
for the maintenance of the REM sleep, this maintenance
being obtained by means of the modulation of the serotoner-
gic activity [24]. Considering the regulation of LHb in seroto-
nergic system, it is reasonable to think that LHb is involved in
the regulation of sleep and mood, since, in accordance with
the obtained evidences, the hyperactivity of LHb causes
heterogeneous symptoms such as reduced motor activity
and alteration in REM sleep, which are typical of MD. [24].3. Comorbidity of the primary sleep disorders
and MD
Certain primary sleep disorders, such as obstructive sleep
apnea (OSA) and restless legs syndrome (RLS), are more
common in patients with MD than in the general population.
OSA is deﬁned by frequent episodes of partial (hypopnea) or
complete (apnea) obstruction of the superior airway during
sleep [25]. It is associated with MD in an odds ratio of 2.4 in
men and 5.2 in women [26]. The high comorbidity of OSA
with depression indicates that both disorders share a com-
mon neurobiological risk factor [27]. The former is demon-
strated by studies of cerebral images which suggest that the
hypoxemia from OSA has an impact on mood [28]. In addi-
tion, MD and OSA have been associated with metabolic
syndrome.
It has been postulated that the reduction of serotonin
levels in MD worsens the function of the superior airway
dilating muscles, a factor that could contribute to OSA;
however, this is not demonstrated properly since antidepres-
sants do not improve OSA; besides, the ﬁrst treatment option
for this pathology is the continuous positive airway pressure
(CPAP) [29].
As far as RLS is concerned, this is a neurological disorder
characterized by an irresistible urgency in moving the legs,
S l e e p S c i e n c e 7 ( 2 0 1 4 ) 1 6 5 – 1 6 9 167especially during rest. This symptom worsens during the
night and improves when walking [30].
In an additional study, it has been demonstrated that
26% of patients with MD presented symptoms of RLS,
concluding that MD is a risk factor for RLS (with an odds
ratio of 1.64). Ohayon, in a telephonic survey, found out
that psychiatric disorders have a 50% risk factor to develop
RLS [31,32].
The elevated comorbidity of RLS and MD is explained in
part by dopamine hypofunction in patients with RLS who also
suffer from chronic insomnia, because they have also a risk
factor to develop MD [31,33]. Narcolepsy is a neurological
disease characterized by irresistible sleep episodes, besides
alterations on the REM sleep, caused by hypocretin deﬁ-
ciency. Neuroanatomical studies indicated that hypocretin
projections are widespread, including limbic structures, the
locus ceruleus and the raphe nucleus. Due to the latter, it
regulates mood and several neuroendocrinal functions [34].
According to Ohayon's investigation, 19.2% of all narcoleptic
patients demonstrated MD, in comparison with only 6.4% of
the general population [35]. Some of the additional mechan-
isms which could also explain the comorbidity of MD in
narcolepsy are obesity or overweight, physical inactivity,
excessive daytime sleepiness, involvement of quality of life
of the patient as well as subjacent medical and sleep
disorders.4. Alterations in sleep architecture in patients
with MD
A signiﬁcant proportion of patients with MD exhibit altera-
tions in sleep architecture, in comparison with good slee-
pers. These alterations include a decrease of the slow wave
sleep, reduction of latency after the ﬁrst episode of REM
sleep, as well as an increase in the percentage and density
of REM (in other words, increase in eye movements per
minute during REM sleep) [36], the latter being associated
with nightmares and vivid dreams. They also present a
decrease in sleep efﬁciency, which is related with an
increase in sleep latency and with awakenings after the
beginning of sleep (WASO) [37]. Some studies with patients
with history of MD demonstrated that the alterations in
sleep architecture will persist during the remission even
with the posterior withdrawal of the antidepressant [38]. In
general, relapses and the improvement of depressive symp-
toms are frequently preceded by alterations in sleep archi-
tecture [39].5. Antidepressant effect and
electroencephalogram
Electroencephalogram (EEG) shows major alpha wave activity
with the eyes closed in patients with MD, which is interpreted
as a decrease in cortical activity. Besides, EEG has also been
utilized to point out that patients with MD who respond to
ﬂuoxetine, imipramine and amytriptilin, have major alpha
power, especially at the occipital level [40]. In another study,
depressed patients who responded to ﬂuoxetine differedfrom nonresponders in the asymmetry of the alpha rhythm,
which indicated a major activation of the right brain hemi-
sphere in comparison with the left [15].
Tarn et al. found a signiﬁcant decrease in beta activity at
4 weeks of treatment with amytriptilin [41].
Considering the effects of antidepressants upon sleep, the
potency of these drugs in suppressing the REM sleep differ,
for example, clomipramine and fenelzine do completely
suppress REM sleep. It has been considered that since the
majority of antidepressants suppress REM sleep, this sup-
pression could be due to the antidepressants; however,
trimipramine, mirtazapine and bupropione increase REM
sleep [15]. The polysomnographic abnormalities that are
characteristic of MD improve with antidepressant therapy,
although ﬂuoxetine does not restore the normal sleep pattern
in patients with remitted depression [42].6. Treatment of MD and sleep alterations
The treatment of sleep alterations (speciﬁcally insomnia) is
divided into pharmacological and non-pharmacological.
Considering the pharmacological one, Franzen et al. stu-
died depressed patients with persistent insomnia treated
with selective inhibitors of serotonin reuptake, which were
assigned to a placebo or Zolpidem (agonist of the benzodia-
zepine receptors). Compared with the placebo group, patients
treated with Zolpidem improved their diurnal function and
their quality of sleep [43].
Sedative antidepressants such as mirtazapine, trimipra-
mine and Amytriptilin are frequently prescribed in clinical
practice for MD and insomnia, concomitantly, although little
evidence supports its long-term usage [44].
On the other hand, Trazodone is an antidepressant with a
mechanism of action that involves the inhibition of the
serotonin transporter and antagonism to the 5HT2A and
5HT2C receptors, besides having antihistaminergic properties
and, in a small proportion, some anticholinergic property. It
is effective upon the reduction of sleep alterations in
depressed patients due to its sedative effects [45].
A novel antidepressant is Agomelatine, which is an ago-
nist of the MT1 and MT2 receptors and an antagonist of the
5HT2C receptors. From its effects upon sleep, we can point
out the increase in sleep efﬁciency, improvement in terms of
quality and quantity of sleep, increase in slow wave sleep and
normalization of REM sleep in MD [46,47].
From the non-pharmacological treatment, we include
behavioral interventions such as the instructions for the
control of stimuli and sleep restrictions. The Behavioral
Cognitive Therapy for insomnia encompasses cognitive com-
ponents to correct dysfunctional beliefs towards sleep. These
interventions have been demonstrated as effective in improv-
ing sleep [43].
Manber et al. evaluated the Behavioral Cognitive Therapy
in patients with MD and insomnia, where they found
improvement in insomnia symptoms as well as in productiv-
ity, energy, severity of the depressive symptoms, suicidal
thoughts and self-esteem [48].
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There is a close association between sleep alterations and
depression, leading to the development of several neurobio-
logical models of study which try to explain such relation-
ship. However, the presence of abnormalities during sleep is
a predictive sign for the beginning or a relapse of MD. There
are effective treatments for insomnia in MD, highlighting
Zolpidem and Agomelatine. From the nonpharmacological
point of view, the Behavioral Cognitive Therapy seems to be
effective upon insomnia as well as for the symptoms of MD.
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